Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections

Sonia Luque, Nuria Campillo, Francisco Álvarez-Lerma, Olivia Ferrández, Juan Pablo Horcajada, Santiago Grau

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

© 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica In this prospective observational study performed in 12 hospitalized patients with proven or suspected invasive fungal infection treated for a mean of 14 days with micafungin (MCF), 8 of whom with pre-existing liver function impairment, plasma levels of MCF at steady state were not correlated with liver function tests at the beginning of treatment. Liver function remained stable or even improved in all patients, except in one in which MCF was discontinued due to liver toxicity.
Original languageEnglish
Pages (from-to)652-654
JournalEnfermedades Infecciosas y Microbiologia Clinica
Volume34
Issue number10
DOIs
Publication statusPublished - 1 Dec 2016

Keywords

  • Hepatotoxicity
  • Micafungin
  • Therapeutic drug monitoring

Fingerprint Dive into the research topics of 'Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections'. Together they form a unique fingerprint.

  • Cite this